Efficacy observation on the treatment of a novel regimen based on boanmycin for patients with refractory non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2011.10.006
- VernacularTitle:以博安霉素为主的新方案治疗难治性非霍奇金淋巴瘤的疗效观察
- Author:
Xilin CHEN
;
Yong DA
;
Xiubin XIAO
;
Shihua ZHAO
;
Shuang WANG
;
Qiushi YANG
;
Lanlan SHAO
;
Yixin YANG
;
Hang SU
;
Weijing ZHANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Drug therapy,combination;
Boanmycin
- From:
Journal of Leukemia & Lymphoma
2011;20(10):587-589,601
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive non-Hodgkin lymphoma (NHL).MethodsSix consecutive patients with recurrent or refractory aggressive NHL were treated with B-VIP regimen,boanmycin (5 mg/m2 on Days 1,4,8,12 and 15),vincristine (1.4 mg/m2 on Days 1,8 and 15),ifosfamide (1.2 g/m2 on Days 1,2,3 and 15,16,17) and prednisone (50 mg on Days 1 to 10),every 21 days.All the patients had received ≥5 cycles (average 8.3 cycles) of previous chemotherapy.ResultsSix patients (100 ％) were evaluable for response.The overall objective response rate was 66.7 ％ (4 patients),including 1 case complete (CR) and 3 cases partial responses.Myelosuppression was the most frequent serious complication of this regimen.ConclusionIn the current study,B-VIP was a highly active and safe combination therapy for patients with refractory disease with a poor prognosis or for patients with multiply recurrent aggressive NHL.
